JP2021511802A - 複製可能ウイルスの存在または非存在を評価するための方法および試薬 - Google Patents

複製可能ウイルスの存在または非存在を評価するための方法および試薬 Download PDF

Info

Publication number
JP2021511802A
JP2021511802A JP2020541756A JP2020541756A JP2021511802A JP 2021511802 A JP2021511802 A JP 2021511802A JP 2020541756 A JP2020541756 A JP 2020541756A JP 2020541756 A JP2020541756 A JP 2020541756A JP 2021511802 A JP2021511802 A JP 2021511802A
Authority
JP
Japan
Prior art keywords
seq
gene
sequence
specific
oligonucleotide primer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511802A5 (enExample
Inventor
ルース ベリー
ルース ベリー
エドウィン ウェブ
エドウィン ウェブ
Original Assignee
ジュノー セラピューティクス インコーポレイテッド
ジュノー セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジュノー セラピューティクス インコーポレイテッド, ジュノー セラピューティクス インコーポレイテッド filed Critical ジュノー セラピューティクス インコーポレイテッド
Publication of JP2021511802A publication Critical patent/JP2021511802A/ja
Publication of JP2021511802A5 publication Critical patent/JP2021511802A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020541756A 2018-01-31 2019-01-31 複製可能ウイルスの存在または非存在を評価するための方法および試薬 Pending JP2021511802A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862624801P 2018-01-31 2018-01-31
US62/624,801 2018-01-31
PCT/US2019/016194 WO2019152747A1 (en) 2018-01-31 2019-01-31 Methods and reagents for assessing the presence or absence of replication competent virus

Publications (2)

Publication Number Publication Date
JP2021511802A true JP2021511802A (ja) 2021-05-13
JP2021511802A5 JP2021511802A5 (enExample) 2022-02-02

Family

ID=65441120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541756A Pending JP2021511802A (ja) 2018-01-31 2019-01-31 複製可能ウイルスの存在または非存在を評価するための方法および試薬

Country Status (5)

Country Link
US (2) US11535903B2 (enExample)
EP (1) EP3746569A1 (enExample)
JP (1) JP2021511802A (enExample)
CN (1) CN111918972A (enExample)
WO (1) WO2019152747A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45783A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Procédés d'évaluation de la présence ou de l'absence d'un virus compétent pour la réplication
JP2021511802A (ja) 2018-01-31 2021-05-13 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法および試薬
CN111910015A (zh) * 2019-05-08 2020-11-10 深圳宾德生物技术有限公司 一种检测复制型慢病毒的探针、引物对、荧光定量pcr试剂盒及方法
JP7726874B2 (ja) * 2019-10-11 2025-08-20 カタログ テクノロジーズ， インコーポレイテッド 核酸セキュリティーおよび認証
GB202003412D0 (en) 2020-03-09 2020-04-22 Oxford Biomedica Ltd Replication competent virus assay
CN112505126B (zh) * 2020-12-16 2023-03-24 中国科学院重庆绿色智能技术研究院 检测金属离子影响诱导HIV-1的Tat蛋白水解的方法
CN112877475A (zh) * 2021-02-19 2021-06-01 北京鼎成肽源生物技术有限公司 一种检测rcl的引物探针组合、试剂盒和检测方法
CN113403343A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备
CN113528706A (zh) * 2021-07-13 2021-10-22 苏州博腾生物制药有限公司 三通道双淬灭探针检测可复制性慢病毒的试剂及其检测方法
CN113699278A (zh) * 2021-09-17 2021-11-26 深圳因诺免疫有限公司 一种基于q-PCR法检测复制型逆转录病毒的引物、试剂盒及检测方法
CN114958983B (zh) * 2021-11-04 2023-03-24 湖州申科生物技术股份有限公司 分析和检测慢病毒载体介导的目的基因的拷贝数的方法
CN114369687A (zh) * 2022-01-29 2022-04-19 宁波熙宁检测技术有限公司 同时检测VSVG和ALB基因的多重qPCR反应体系的建立方法
CN114410844A (zh) * 2022-01-29 2022-04-29 宁波熙宁检测技术有限公司 多重qPCR检测GALV和ALB拷贝数判定CAR-T细胞产品中RCR阴阳性的方法
CN117568446A (zh) * 2022-08-08 2024-02-20 台达电子国际（新加坡）私人有限公司 检测病毒感染性的样本前处理试剂盒及方法
KR102804750B1 (ko) * 2022-10-20 2025-05-12 성균관대학교산학협력단 바이러스 생산 세포 검출용 멀티플렉스 pcr 프라이머 및 프로브
CN116219069A (zh) * 2022-11-11 2023-06-06 湖州申科生物技术股份有限公司 一种检测可复制性慢病毒的探针、引物、试剂盒及其应用
CN116970737A (zh) * 2023-04-27 2023-10-31 北京艺升医疗科技有限公司 一种复制型慢病毒检测方法
CN117737303A (zh) * 2023-12-14 2024-03-22 浙江恒驭生物科技有限公司 细胞治疗产品中复制型逆转录病毒rcr-galv的检测组合物、方法及试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090028836A1 (en) * 2005-06-01 2009-01-29 Kalle Christof Von Stem and progenitor cell expansion by evi, evi-like genes and setbp1
WO2018023094A1 (en) * 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Methods for assessing the presence or absence of replication competent virus

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4996143A (en) 1985-12-23 1991-02-26 Syngene, Inc. Fluorescent stokes shift probes for polynucleotide hybridization
ATE112314T1 (de) 1988-05-17 1994-10-15 Lubrizol Genetics Inc Pflanzliches ubiquitinpromotorsystem.
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
EP1067134B1 (en) 1991-11-07 2004-07-28 Nanotronics, Inc. Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
JP4540754B2 (ja) 1996-06-04 2010-09-08 ユニバーシティ オブ ユタ リサーチ ファウンデーション Ｐｃｒ中のハイブリダイゼーションのモニタリング
ES2253778T3 (es) 1996-06-04 2006-06-01 University Of Utah Research Foundation Sistema y metodos de monitorizacion de una amplificacion de adn mediante fluorescencia.
WO1998032869A1 (en) 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
WO2002014555A2 (en) 2000-08-11 2002-02-21 University Of Utah Research Foundation Single-labeled oligonucleotide probes
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
KR100440852B1 (ko) 2001-05-10 2004-07-19 주식회사 바이로메드 레트로바이러스에 특이적인 올리고뉴클레오티드 프라이머및 이를 이용한 레트로바이러스 농도 측정방법
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1534847B1 (en) 2002-09-03 2015-10-28 Oxford Biomedica (UK) Limited Retroviral vector and stable packaging cell lines
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2007008309A2 (en) 2005-06-01 2007-01-18 Children's Hospital Medical Center Stem and progenitor cell expansion by evi, evi-like genes and setbp1
ES2371088T3 (es) 2005-10-05 2011-12-27 F. Hoffmann-La Roche Ag Transferencia de energía no fluorescente.
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
PL2222861T3 (pl) 2007-12-11 2018-04-30 The University Of North Carolina At Chapel Hill Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
CN102154368B (zh) 2010-02-11 2015-01-21 上海比昂生物医药科技有限公司 一种组织特异性兼可调控性慢病毒基因表达载体
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
JP6482461B2 (ja) * 2012-07-13 2019-03-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 投与に関する形質導入ｔ細胞の適合性の評価方法
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
US10072273B2 (en) * 2014-01-10 2018-09-11 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Pseudotyped lentiviral vectors
JP2021511802A (ja) 2018-01-31 2021-05-13 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法および試薬

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090028836A1 (en) * 2005-06-01 2009-01-29 Kalle Christof Von Stem and progenitor cell expansion by evi, evi-like genes and setbp1
WO2018023094A1 (en) * 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Methods for assessing the presence or absence of replication competent virus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MOLECULAR THERAPY - METHODS & CLINICAL DEVELOPMENT, vol. 8, JPN5021006218, 2017, pages 1 - 7, ISSN: 0005162157 *
MOLECULAR THERAPY, vol. 19, JPN6022054873, 2010, pages 557 - 566, ISSN: 0005162160 *
MOLECULAR THERAPY, vol. 26, JPN5021006214, 2017, pages 269 - 279, ISSN: 0005162158 *
MOLECULAR THERAPY, vol. 8, JPN6022054874, 2003, pages 830 - 839, ISSN: 0005162159 *

Also Published As

Publication number Publication date
US11535903B2 (en) 2022-12-27
US20210164062A1 (en) 2021-06-03
CN111918972A (zh) 2020-11-10
US12264371B2 (en) 2025-04-01
US20230193411A1 (en) 2023-06-22
WO2019152747A1 (en) 2019-08-08
EP3746569A1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
US12264371B2 (en) Methods and reagents for assessing the presence or absence of replication competent virus
JP7483373B2 (ja) 複製可能ウイルスの存在または非存在を評価するための方法
JP6868560B2 (ja) 修飾された肝炎転写後調節エレメント
EP3895712B1 (en) Engineered natural killer cells and uses thereof
JP2025063046A (ja) キメラ抗原受容体発現細胞を作製する方法
CN116234558A (zh) 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
US20250305003A1 (en) Genome editing of cells
HK40008412B (en) Methods for assessing the presence or absence of replication competent virus
HK40008412A (en) Methods for assessing the presence or absence of replication competent virus
US20210388384A1 (en) Vectors
HK40061900A (en) Engineered natural killer cells and uses thereof
HK40061900B (en) Engineered natural killer cells and uses thereof
HK1246347B (en) Modified hepatitis post-transcriptional regulatory elements

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200909

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230928